AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02656719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy guided percutaneous tracheostomy
Description: Bronchoscopy guided percutaneous tracheostomy
Study NCT04127097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cartoon group
Description: The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
Study NCT03452215 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mobile Phone Application Educational Resources
Description: Mobile Phone Application Educational Resources
Study NCT03452215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application Educational Resources
Description: Mobile Phone Application Educational Resources
Study NCT03452215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application GWG Tracker
Description: Mobile Phone Application GWG Tracker
Study NCT03679559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention (HIIT program and resistance training)
Description: Complete HIIT program and resistance training
Study NCT03679559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Watch video
Study NCT03679559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03679559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit
Study NCT03679559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03679559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04533113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious tissue selective removal
Description: Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
Study NCT03513666 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug intervention
Description: anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
Study NCT04110314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Gain-framed
Description: Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
Study NCT04110314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Loss-framed
Description: Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
Study NCT04110314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-commitment prompt
Description: Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
Study NCT01045005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration ofOxygen and carbon dioxide
Description: Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
Study NCT01045005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Oxygen and carbon dioxide
Description: Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
Study NCT05687097 — intervention group
Intervention type: DEVICE
Intervention: Home-based sleep screening test or hospital-unattended sleep screening test
Description: ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
Study NCT05687097 — intervention group
Intervention type: DEVICE
Intervention: Cardiovascular beat-to-beat monitoring
Description: CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
Study NCT05687097 — intervention group
Intervention type: DEVICE
Intervention: ECG monitoring
Description: Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
Study NCT02944162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR-NK cells
Description: The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
Study NCT03566004 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Stool specimen collection
Description: The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
Study NCT03822429 — intervention group
Intervention type: DRUG
Intervention: Controlled ovarian stimulation
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles
Study NCT04630704 — intervention group
Intervention type: DEVICE
Intervention: Pedra
Description: Diffuse speckle contrast analysis perfusion system
Study NCT05119842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APrevent® VOIS-Implant
Description: To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
Study NCT04957147 — intervention group
Intervention type: OTHER
Intervention: 12 months of guideline-directed heart failure therapy
Description: Standard guideline-directed heart failure drug +/- device therapy
Study NCT03514277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
Study NCT03514277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 mL bupivacaine 0.5% w/v solution
Study NCT02965105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Catheter
Description: This is a newly developed intermittent catheter
Study NCT02965105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Speedicath
Description: This is a marketed Catheter which is used as comparator
Study NCT00414167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 300 mg per day for 8 weeks
Study NCT00414167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01538966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegvisomant
Study NCT01538966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Study NCT01538966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide
Study NCT04574453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iracross
Description: Administration of max 2ml of Iracross at first visit
Study NCT04574453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iraline
Description: Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
Study NCT02735980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study NCT03019991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Study NCT03019991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
Study NCT03019991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
Study NCT03019991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Study NCT01014247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Single dose of 400 mg
Study NCT01014247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching tablet
Study NCT02501746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinical Care
Description: Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
Study NCT02501746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Clinical Care
Description: Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
Study NCT02501746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Medical Visits
Description: The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic.
Study NCT02501746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfinance Groups
Description: The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
Study NCT03186144 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blodd punction for genetic analysis
Study NCT03153553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
Study NCT03153553 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
Study NCT01809860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: Oral
Study NCT01809860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral
Study NCT03225690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Prevention of remifentanil induced hyperalgesia
Study NCT03225690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serum physiologic
Description: For placebo, serum physiologic will use
Study NCT03952091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ202, Lenalidomide and Dexamethasone
Description: One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
Study NCT03952091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and Dexamethasone
Description: Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
Study NCT04900675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light intervention
Description: Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
Study NCT04900675 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reddish placebo light
Description: Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
Study NCT02954198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: goal trough level 5-12ng/mL
Study NCT02954198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: goal dose 5mg QD
Study NCT02954198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: goal dose 1g BID
Study NCT02954198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: goal trough level 3-8ng/mL
Study NCT05303389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation of 2,3 or 4 column pilon fracture of the tibia
Description: anterior to posterior screws in classic arm and posterolateral approach in new arm group
Study NCT05303389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of 2,3 or 4 column pilon fracture of the tibia
Description: anterior to posterior screws in classic arm and posterolateral approach in new arm group
Study NCT02119442 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcather Valve Implantation
Description: Transcather Valve Implantation
Study NCT01346072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: oral, 30 mg, single dose, one time administration
Study NCT00162916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: 20mg or 40mg, once daily, for 40 weeks
Study NCT00162916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch
Study NCT03599102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOVED Intervention
Study NCT03432442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin once every 24 hours for three administrations
Study NCT01904110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate/Cholecalciferol combination(montly)
Description: once a month
Study NCT01904110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate/Cholecalciferol combination(montly)
Description: once a month
Study NCT01904110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate/Cholecalciferol combination(weekly)
Description: once a week
Study NCT04065243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding diet
Description: Two weeks of overfeeding
Study NCT04065243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric diet
Description: Two weeks of isocaloric weight maintenance
Study NCT00713843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Utrecht
Description: Manual Therapy (6 weeks).
Study NCT00713843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy (six weeks).
Study NCT01114009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
Study NCT01114009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung protective strategy group
Description: Lung protective strategy group received Lung protective strategy without recruitment maneuver
Study NCT01114009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective strategy group
Description: Lung protective strategy group received Lung protective strategy without recruitment maneuver
Study NCT02812589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in Breast MRI
Study NCT04420728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early auto-mode
Description: Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
Study NCT04420728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed auto mode
Description: Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
Study NCT02956538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02956538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo(for thalidomide)
Description: sugar pill manufactured to mimic thalidomide 100mg tablet
Study NCT00712257 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface
Description: treatment for superficial femoral artery instent re-stenosis
Study NCT01617239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)
Study NCT02620683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See above
Study NCT05915273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Aided Design/ Computer Aided Manufacturing Retainers
Description: Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group
Study NCT05915273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lab-based Retainers
Description: The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
Study NCT05915273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chairside Retainers
Description: The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
Study NCT03771963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TDV)
Description: TDV SC injection.
Study NCT01116037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ATS 3f Aortic Bioprosthesis
Description: Equine Pericardial Bioprosthesis for replacement of diseased valve
Study NCT03461198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Restylane® Silk to a defined area of mid to low cheeks